Market Overview - The medical beauty sector experienced a decline of 0.33% on October 14, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Individual Stock Performance - Jinbo Biological (code: 920982) closed at 276.60, up 5.58% with a trading volume of 17,000 shares [1] - *ST Meigu (code: 000615) closed at 3.63, up 4.61% with a trading volume of 326,000 shares [1] - Aimeike (code: 300896) closed at 175.49, down 0.10% with a trading volume of 24,200 shares [1] - Huaxi Biological (code: 688363) closed at 54.02, down 1.15% with a trading volume of 33,100 shares [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 7.7391 million yuan from main funds, while retail funds experienced a net inflow of 1.0341 million yuan [1] - Speculative funds had a net outflow of 8.7732 million yuan [1] Detailed Capital Flow for Individual Stocks - Aimeike had a net outflow of 9.3340 million yuan, down 2.20% [2] - *ST Meigu experienced a net inflow of 1.1847 million yuan, up 1.03% [2] - Huaxi Biological had a significant net outflow of 10.6702 million yuan, down 5.90% [2]

Group 1 - The medical beauty sector experienced a decline of 1.92% on October 13, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] - Major stocks in the medical beauty sector showed mixed performance, with *ST Meigu rising by 5.15% to a closing price of 3.47, while Ai Meike fell by 2.32% to 175.66 [1] Group 2 - The net outflow of main funds in the medical beauty sector was 75.6993 million yuan, while retail investors saw a net inflow of 48.3038 million yuan [1] - Specific fund flows for major stocks indicated that Ai Meike had a net outflow of 51.1050 million yuan, representing a decrease of 10.15% [2] - Huaxi Biological and *ST Meigu also experienced significant net outflows of 15.8278 million yuan and 8.7665 million yuan, respectively [2]

Investment Rating - The report gives a "Buy" rating for the cosmetics and medical beauty industry, particularly highlighting the potential of specific companies like Water Sheep Co., Ltd. [13] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index rising by 1.3% from September 29 to October 10, 2025, which is lower than the overall market performance [3][4] - The upcoming Tmall Double 11 event is expected to boost sales, with domestic brands actively participating with competitive discounts [8] - Water Sheep Co., Ltd. is identified as a leading technology-driven beauty company, with stable revenue projections and improving profit margins [9][10] Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Cosmetics Index increasing by 1.2%, lagging behind the Shenwan A Index by 0.4 percentage points [3][4] - The top-performing stocks in the sector include Jiaheng Home Care (+35.0%), Yiyi Co., Ltd. (+18.6%), and Yanjing Co., Ltd. (+15.6%) [5] Upcoming Events - Tmall's Double 11 sales event is set to begin on October 15, 2025, with major domestic brands like Proya and Maogeping expected to participate actively [8] Company Focus: Water Sheep Co., Ltd. - Water Sheep Co., Ltd. has a dual business model of proprietary and CP agency brands, with projected revenues stabilizing between 4 to 5 billion yuan from 2021 to 2024 [9] - The company is expected to achieve net profits of 258 million, 331 million, and 398 million yuan for the years 2025, 2026, and 2027, respectively, reflecting significant growth [10][13] Market Trends - The overall retail sales of cosmetics in August 2025 grew by 5.1%, indicating a recovery in consumer demand [17] - The domestic market is seeing a shift in market share, with local brands gaining ground against international competitors [25] E-commerce Insights - Data shows that domestic brands are performing well on platforms like Douyin and Tmall, with significant growth in GMV for brands like Proya and Maogeping [14][15] Company Developments - Proya has filed for an IPO in Hong Kong, with stable revenue growth and a strong online presence [19] - The report highlights the strategic moves of various companies, including partnerships and new product launches, to enhance their market positions [24][23]

Core Insights - Huaxi Biological has been selected for the Xinhua News Agency's brand project, aiming for deep collaboration in brand communication, think tank research, and resource integration [1][3] - The partnership is expected to enhance the high-quality development of China's biotechnology industry and showcase the innovation and brand strength of Chinese enterprises [3] Company Overview - Huaxi Biological, established in 2000, is a leading global manufacturer of anti-aging substances, particularly hyaluronic acid [4] - The company has developed a complete ecosystem from raw materials to end products, with business operations extending into pharmaceuticals, medical aesthetics, nutritional science, and dermatology [4] - Huaxi Biological has launched several brands, including "Runbaiyan," "Kuaidi," "Mibeier," "Jihuo," and "Huaxi Dangkang" [4] Industry Context - The collaboration comes at a time when the global biotechnology wave intersects with China's "Healthy China" strategy, highlighting significant development opportunities in the biomanufacturing sector [4] - The Xinhua News Agency's brand project has been operational since 2017, providing professional, systematic, and international services to over a hundred Fortune Global 500 companies and leading enterprises in various industries [4]

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the global biomanufacturing industry, including its development status and trends [5]. - It compares the biomanufacturing sectors of China and the United States, highlighting competitive dynamics [5]. - Future development trends in biomanufacturing are discussed, indicating potential growth areas [5]. Group 2: Policy Landscape - The report outlines major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. - It details foreign biomanufacturing industry policies and their implications for the sector [5]. - Domestic policies related to biomanufacturing are also analyzed, providing insights into regulatory frameworks [5]. Group 3: Industry Map and Applications - The white paper presents a comprehensive map of the Chinese biomanufacturing industry, identifying key players and their roles [5]. - It analyzes the biomanufacturing industry chain and key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - Specific applications of biomanufacturing in various sectors are highlighted, showcasing its versatility and potential impact [5]. Group 4: Key Enterprises and Investment Landscape - The report identifies ten leading enterprises in the Chinese biomanufacturing industry, providing insights into their operations and market positions [6]. - It summarizes the strategic directions of 15 listed companies in synthetic biology, indicating their focus areas and growth strategies [6]. - The investment landscape for synthetic biology in China is examined, detailing funding trends and opportunities from 2024 to mid-2025 [6]. Group 5: Challenges and Recommendations - The white paper discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [6].

格隆汇10月11日｜有投资者在互动平台向华熙生物提问：请介绍合成生物平台复用性。麦角硫因/红景 天苷等研发中，平台能否快速复制至CDMO代工业务？(如为药企生产核苷酸)；或者国际技术授权(类似 Ginkgo的ADEPT模式)？ 华熙生物回复称，华熙生物的合成生物平台在基因编辑、菌株高效构建、代谢 路径优化、工艺开发等方面的技术成熟度较高，中试成果转化中心以模块化设计与柔性化生产为核心， 可快速实现工艺放大与产业化转移。华熙生物所积累的平台技术与经验，可赋能应用于功能糖、蛋白 质、多肽、氨基酸、核苷酸、天然活性物类这六大类物质的开发，实现技术模块跨品类复用并延伸至 CDMO代工，以受托生产的业务形式帮助客户降低研发成本，缩短周期。所储备的技术成果，也可以通 过技术授权转让与合作开发的形式，构建公司授权合作生态圈。 ...

中国香妆行业面临从增量竞争转向存量博弈的竞争格局。 虽然中国香妆行业市场规模从2023年开始已连续两年超万亿元，成为全球第一大化妆品消费市场，但如今的中国美妆市场也迎来全新的竞争格局：从"增量 竞争"转向"存量博弈"，从渠道驱动转向品牌驱动。 在近期举办的2025CAME上，记者在走访一些企业后了解到，如今的中国化妆品行业在原料创新、功效验证、技术转化等方面都有了突破。 不少业内人士表示，从核心技术攻关到品牌价值重构，从单点竞争到生态共建，中国香妆产业正通过深化科技驱动、重塑品牌逻辑、构建协同网络，培育新 质生产力，重塑其在全球价值链中的话语权。 突破原料"卡脖子"，企业进入"收获期" "很多人说化妆品没什么用，只是一个安慰品，其实不是的。化妆品一定是有价值的，它要真正为皮肤健康提供帮助，让消费者切实感受到获得感。" 华熙 生物科技股份有限公司董事长兼总裁赵燕日前在2025CAME上接受媒体采访时表示。 一位来自广东的参展商告诉记者，自从有了电商直播，国内美妆企业更卷，在一些社交平台上，贴牌的新品牌很容易将业绩在短时间内做上去，但过两年回 头去看，这家企业就没有了。"做化妆品需要做品牌讲故事，但不只是做品牌讲 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-039 华熙生物科技股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第一次临时股东会 召开日期时间：2025 年 10 月 27 日 10 点 00 分 召开地点：北京市朝阳区建国门外大街甲六号华熙国际中心 D 座 36 层会议 室 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 二、 会议审议事项 网络投票起止时间：自2025 年 10 月 27 日 至2025 年 10 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年10月27日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事 ...

华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 证券代码：688363 证券简称：华熙生物 华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 华熙生物科技股份有限公司 2025 年第一次临时股东会会议资料 2025 年 10 月 华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 2025 年第一次临时股东会会议资料目录 | 华熙生物科技股份有限公司 | | 2025 | 年第一次临时股东会会议须知 | 1 | | --- | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | | 2025 | 年第一次临时股东会会议议程 | 4 | | 议案一 2025 | 关于续聘公司 | 年度审计机构的议案 | | 6 | | 华熙生物科技股份有限公司拟聘任会计师事务所的基本情况 | | | | 7 | 2025 年第一次临时股东会会议须知 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东会的正常秩序，保证股东会的议事效率，确保本次股东会如期、顺 利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章程》《华 熙 ...

Market Overview - The medical beauty sector experienced a decline of 0.5% on October 10, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - The following stocks in the medical beauty sector showed varying performance: - *ST Meigu (000615)*: Closed at 3.30, down 0.30% with a trading volume of 64,200 shares [1] - Aimeike (300896): Closed at 179.84, down 0.32% with a trading volume of 27,000 shares [1] - Huaxi Biological (688363): Closed at 55.78, down 0.76% with a trading volume of 38,500 shares [1] - Jinbo Biological (920982): Closed at 267.48, down 1.95% with a trading volume of 9,733 shares [1] Capital Flow - The medical beauty sector saw a net inflow of 14.16 million yuan from main funds, while retail funds experienced a net outflow of 8.85 million yuan [1] - Detailed capital flow for specific stocks includes: - Aimeike (300896): Net outflow of 11.73 million yuan, down 2.40% [2] - *ST Meigu (000615)*: Net outflow of 1.17 million yuan, down 5.51% [2] - Huaxi Biological (688363): Net outflow of 3.72 million yuan, down 1.72% [2]